Nurix Therapeutics (NRIX) Operating Margin (2019 - 2025)
Historic Operating Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 612.03%.
- Nurix Therapeutics' Operating Margin fell 1253000.0% to 612.03% in Q4 2025 from the same period last year, while for Nov 2025 it was 340.16%, marking a year-over-year increase of 503600.0%. This contributed to the annual value of 340.16% for FY2025, which is 503600.0% up from last year.
- According to the latest figures from Q4 2025, Nurix Therapeutics' Operating Margin is 612.03%, which was down 1253000.0% from 1157.65% recorded in Q3 2025.
- Nurix Therapeutics' 5-year Operating Margin high stood at 87.25% for Q2 2023, and its period low was 1157.65% during Q3 2025.
- Over the past 5 years, Nurix Therapeutics' median Operating Margin value was 400.65% (recorded in 2022), while the average stood at 420.45%.
- As far as peak fluctuations go, Nurix Therapeutics' Operating Margin skyrocketed by 4187700bps in 2023, and later crashed by -7238200bps in 2025.
- Over the past 5 years, Nurix Therapeutics' Operating Margin (Quarter) stood at 513.16% in 2021, then plummeted by -40bps to 717.82% in 2022, then skyrocketed by 58bps to 299.06% in 2023, then crashed by -63bps to 486.73% in 2024, then decreased by -26bps to 612.03% in 2025.
- Its Operating Margin stands at 612.03% for Q4 2025, versus 1157.65% for Q3 2025 and 109.68% for Q2 2025.